Valproic Acid Enhances the Anti-tumor Effect of Pegylated Interferon-α Towards Pancreatic Cancer Cell Lines

被引：0
作者：
Sugimoto, Koji [1 ]
Shimada, Mitsuo [1 ]
Utsunomiya, Toru [1 ]
Morine, Yuji [1 ]
Imura, Satoru [1 ]
Ikemoto, Tetsuya [1 ]
Iwahashi, Shuichi [1 ]
机构：
[1] Univ Tokushima, Dept Surg, Inst Hlth Biosci, Tokushima 7708503, Japan
来源：
ANTICANCER RESEARCH | 2014年 / 34卷 / 07期
关键词：
Histone deacetylase inhibitor; valproic acid; pegylated interferon-alpha; pancreatic cancer; HISTONE DEACETYLASE INHIBITORS; REGULATORY FACTOR-8; IN-VITRO; COMBINATION THERAPY; IFN-ALPHA; EXPRESSION; APOPTOSIS; ANGIOGENESIS; REGRESSION; CARCINOMA;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Valproic acid (VPA) acts as a specific inhibitor of class I HDACs and it use has been proven to be safe since a long time. Materials and Methods: In the present study, we investigated the effect of VPA in the combination with pegylated interferon-alpha (PEG-IFN alpha) in inhibition of cell proliferation of human pancreatic cancer cell lines. Results: VPA enhanced the effect of PEG-IFNa, and the effect was decreased by the caspase inhibitor. VPA alone and VPA in combination with PEG-IFNa increased the expression of interferon-alpha receptor and interferon regulatory factor 8. Conclusion: The combination of VPA and PEG-IFN alpha can be useful for the treatment of pancreatic cancer.
引用
收藏
页码：3403 / 3409
页数：7
相关论文
共 45 条
[1]   Targeted Treatment of Differentiated and Medullary Thyroid Cancer [J].
Bales, Shannon R. ;
Chopra, Inder J. .
JOURNAL OF THYROID RESEARCH, 2011, 2011
[2]   CRA-024781:: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo [J].
Buggy, Joseph J. ;
Cao, Z. Alexander ;
Bass, Kathryn E. ;
Verner, Erik ;
Balasubramanian, Sriram ;
Liu, Liang ;
Schultz, Brian E. ;
Young, Peter R. ;
Dalrymple, Stacie A. .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (05) :1309-1317
[3]   Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties [J].
Caraglia, Michele ;
Dicitore, Alessandra ;
Marra, Monica ;
Castiglioni, Sara ;
Persani, Luca ;
Sperlongano, Pasquale ;
Tagliaferri, Pierosandro ;
Abbruzzese, Alberto ;
Vitale, Giovanni .
PROTEIN AND PEPTIDE LETTERS, 2013, 20 (04) :412-423
[4]   Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect [J].
Dickinson, Michael ;
Johnstone, Ricky W. ;
Prince, H. Miles .
INVESTIGATIONAL NEW DRUGS, 2010, 28 :S3-S20
[5]   Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors [J].
Duenas-Gonzalez, Alfonso ;
Candelaria, Myrna ;
Perez-Plascencia, Carlos ;
Perez-Cardenas, Enrique ;
de la Cruz-Hernandez, Erick ;
Herrera, Luis A. .
CANCER TREATMENT REVIEWS, 2008, 34 (03) :206-222
[6]   Interferon-γ induces regression of epithelial cell carcinoma:: critical roles of IRF-1 and ICSBP transcription factors [J].
Egwuagu, CE ;
Li, W ;
Yu, CR ;
Lin, MCM ;
Chan, CC ;
Nakamura, T ;
Chepelinsky, AB .
ONCOGENE, 2006, 25 (26) :3670-3679
[7]   Activation of the Type I Interferon Pathway Is Enhanced in Response to Human Neuronal Differentiation [J].
Farmer, Jocelyn R. ;
Altschaefl, Kate M. ;
O'Shea, K. Sue ;
Miller, David J. .
PLOS ONE, 2013, 8 (03)
[8]   Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer [J].
Feng, Wan ;
Zhang, Bin ;
Cai, Dawei ;
Zou, Xiaoping .
CANCER LETTERS, 2014, 347 (02) :183-190
[9]   Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages [J].
Gillen, Sonja ;
Schuster, Tibor ;
zum Bueschenfelde, Christian Meyer ;
Friess, Helmut ;
Kleeff, Joerg .
PLOS MEDICINE, 2010, 7 (04)
[10]   Modern management of pancreatic carcinoma [J].
Goldstein, D ;
Carroll, S ;
Apte, M ;
Keogh, G .
INTERNAL MEDICINE JOURNAL, 2004, 34 (08) :475-481
12345